NYMC Faculty Publications
Title
A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients with Clinical or Laboratory Tumor Lysis Syndrome
Document Type
Article
Publication Date
March 2017
Department
Pediatrics
Abstract
BACKGROUND: The aim of the study was to compare reductions in uric acid (UA), length of stay (LOS), and hospitalization costs in patients with tumor lysis syndrome (TLS) treated with rasburicase or allopurinol. PATIENTS AND METHODS: This retrospective study of administrative data included hospitalized pediatric and adult patients who had clinical or laboratory TLS and received rasburicase or allopurinol. Each rasburicase-treated patient was propensity scorse-matched with 4 allopurinol-treated patients. Mean changes in UA within
Recommended Citation
Cairo, M., Thompson, S., Tangirala, K., & Eaddy, M. (2017). A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients with Clinical or Laboratory Tumor Lysis Syndrome. Clinical Lymphoma, Myeloma & Leukemia, 17 (3), 173-178. https://doi.org/10.1016/j.clml.2016.11.003
